no effect on resting BP and heart rate (HR), but attenuates an l-glutamate-induced increase in BP. 7 These results suggest that the effects of estrogen on BP and HR in central autonomic nuclei are regionally specific.
T he incidence and severity of hypertension have been shown to be lower in premenopausal women than agematched men, as well as in female animals of hypertensive models. [1] [2] [3] Estrogen has been demonstrated to have beneficial effects on cardiovascular function through actions not only on the heart and vasculature but also on the central nervous system (CNS). 4 Microinjections of estrogen into the parabrachial nucleus, the nucleus of the solitary tract (NTS), or the rostroventrolateral medulla (RVLM) of male rats have been shown to decrease resting blood pressure (BP) and increase baroreceptor sensitivity. 5, 6 In contrast, microinjection of estrogen into the hypothalamic paraventricular nucleus (PVN) has ERα is important in the NTS. 9 An accurate understanding of how central estrogens protect against the development of hypertension depends directly on a more detailed knowledge of the precise role of both ER subtypes in different brain areas involved in BP regulation. Indeed, the specific roles of ERα and ERβ in BP regulation have been studied in mice harboring targeted deletions of ERα and ERβ and in animals with acute treatment of ER selective agonist. Estrogen activation of ERα, particularly that expressed centrally, is protective against the baroreceptor dysfunction and hypertension induced by angiotensin II in female mice. 10, 11 In recent microinjection studies on the effects of estrogen on BP, ERβ seems to mediate attenuated effects of estrogen on resting BP in the RVLM and glutamate-induced increase in BP in the PVN. 7, 12 Aldosterone (Aldo) is known to be an independent risk factor for cardiovascular disease, 13 and the sites of action for Aldo pressor effects have been shown to include the CNS. 14 Previously, we have demonstrated a clear role of the CNS in sex differences in the hypertensive effects of Aldo/salt. 15 In these studies, central infusion of estrogen attenuated Aldoinduced hypertension in both males and ovariectomized (OVX) females, whereas central blockade of ERs by a nonselective antagonist augments Aldo pressor effects in intact females. Using selective ERα or ERβ agonist and methods to specifically silence ERα or ERβ expression in the PVN and RVLM, the present study further investigated regional specificity of different ER subtypes in the protective actions of estrogen in the female rat model of Aldo-induced hypertension.
Methods
Ninety-nine Sprague-Dawley female rats (10-12 weeks old, Harlan) were used. The rats were divided into 12 groups: (1-3) intracerebroventricular (icv) infusions of vehicle, a selective ERβ agonist diarylpropionitrile (DPN) or a selective ERα agonist propyl-pyrazole-triol (PPT) in OVX females (n=6 per group); (4-6) icv injections of scrambled recombinant adeno-associated virus (AAV) carrying small interference (si) RNA (AAV-siRNA-scramble [SCM]), AAVsiRNA to silence ERα (AAV-siRNA-ERα), AAV-siRNA to silence ERβ (AAV-siRNA-ERβ) in intact females (n=5 each group); (7-9) PVN microinjections of siRNA-SCM, siRNA-ERα, or siRNA-ERβ in intact females (n=6 per group); (10-12) RVLM microinjections of siRNA-SCM, siRNA-ERα, or siRNA-ERβ in intact females (n=6 per group). All of the groups were infused subcutaneously with Aldo combined with 1% NaCl as the sole drinking fluid, and 1% NaCl intakes were measured daily. Six additional groups treated in the same way as group 7 to 12, but without physiological studies, were performed for assessments of mRNA expression of ERα or ERβ in the RVLM or PVN (n=5 per group).
For reactive oxygen species (ROS) imaging studies, neurons were collected from the PVN of 8-day-old rat pups from Sprague-Dawley mothers (Harlan). The cultured cells were divided into 4 groups: (1) incubation with siRNA-SCM and vehicle (control), (2) incubation of siRNA-SCM and Aldo, (3) incubation of siRNA-ERα and Aldo, and (4) incubation of siRNA-ERβ and Aldo.
All experiments were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the University of Iowa Animal Care and Use Committee.
Additional details for surgical procedures and experimental protocols are available in the online-only Data Supplement.
Data Analysis
Mean arterial pressure (MAP) and HR are presented as mean daily values. Difference scores for MAP and HR were calculated for each animal based on the mean of the 5-day baseline subtracted from the mean of the final 5 days of treatment. One-way ANOVAs for the experimental groups were then conducted on the mean values of calculated difference scores. After establishing a significant ANOVA, post hoc analyses were performed with Tukey multiple comparison tests between pairs of mean change scores. To test differences in the mean of the 5-day baseline versus the mean of the final 5 days of treatment, paired t tests were performed in animals within same group. The same statistical methods were used to analyze the changes in HR, 1% NaCl intake, or differences in Aldo-induced ROS production in neurons and mRNA expression of ERα or ERβ in the PVN or RVLM treated with siRNA-SCM, siRNA-ERα, or siRNA-ERβ. All data are expressed as mean±SE. Statistical significance was set at P<0.05.
Results

Effect of icv Infusions of Selective ER Agonist on Aldo/NaCl-Induced Hypertension in OVX Females
Baseline values for MAP and HR were comparable before and after icv ER agonist infusions across all groups of OVX females (not shown in Figure 1A ). Twenty-one days of Aldo/NaCl treatment resulted in a 21.1±2.1 mm Hg increase in MAP in OVX females with icv vehicle infusions. Icv infusion of either PPT or DPN for 21 days significantly attenuated Aldo/NaCl-induced hypertension (∆11.4±2.5 and ∆11.1±1.6 mm Hg, respectively; P<0.05; Figure 1A and 1B). Systemic Aldo infusions produced significant, comparable increases in 1% NaCl intake (P>0.05; Figure  S1A in the online-only Data Supplement) and decreases in HR ( Figure S1B ) in all groups when compared with rats given Aldo vehicle alone (34.5±6.4 mL/d; not shown in Figure S1A ). Baseline values for MAP and HR were comparable before and after icv siRNA microinjection in all groups of intact female rats (not shown in Figure 2A ). In icv siRNA-SCM-injected females, 21 days of Aldo/NaCl treatment resulted in a slight but significant increase in MAP (∆5.7±1.9 mm Hg; P<0.05). Icv injections of either siRNA-ERα or siRNA-ERβ significantly augmented Aldo-induced increase in MAP (∆14.3±1.5 and ∆20.5±2.1 mm Hg, respectively; P<0.05; Figure 2A and 2B). Systemic Aldo infusions also produced significant, comparable increases in 1% NaCl intake ( Figure S2A ) and decreases in HR ( Figure S2B ) in all groups.
Effect of Bilateral PVN Microinjections of siRNA-SCM, siRNA-ERα, or siRNA-ERβ on Aldo/NaClInduced Hypertension in Intact Females
To determine whether ERs within the PVN are involved in female resistance to Aldo/NaCl hypertension, the effects of siRNA-ERα or siRNA-ERβ were evaluated. Baseline values for MAP and HR were comparable before and after siRNA PVN microinjection (Table S1 ). Systemic Aldo produced a slight but significant increase in MAP in PVN siRNA-SCMinjected females (∆7.8±1.3 mm Hg; P<0.05). Bilateral PVN microinjection of siRNA-ERβ significantly augmented the pressor effect of Aldo (∆16.1±1.3 mm Hg; P<0.05). However, microinjection of siRNA-ERα resulted in only a 11.2±1.8 mm Hg change in MAP that was not significantly different from the increase seen in siRNA-SCM-injected females ( Figure 3A and 3B). Systemic Aldo infusions also produced significant but comparable increases in 1% NaCl intake ( Figure S3A ) and decreases in HR ( Figure S3B ) in all groups.
Effect of RVLM Microinjections of siRNA-SCM, siRNA-ERα, or siRNA-ERβ on Aldo/NaCl-Induced
Hypertension in Intact Females
To determine whether ERs within the RVLM are involved in female resistance to Aldo/NaCl hypertension, the effects of siRNA-ERα and siRNA-ERβ were evaluated. Baseline values for MAP and HR were comparable before and after RVLM microinjection of siRNA. Systemic Aldo resulted in a slight but significant increase in MAP in RVLM siRNA-SCM-injected females (∆7.7±0.9 mm Hg; P<0.05). Bilateral RVLM microinjection of siRNA-ERβ significantly augmented MAP induced by Aldo infusion (∆16.1±2.7 mm Hg; P<0.05). However, microinjection of siRNA-ERα resulted in only an 8.1±2.9 mm Hg increase in MAP that was not significantly different from the increase in siRNA-SCMinjected females ( Figure 4A and 4B). Systemic Aldo infusions also produced significant, but comparable, increases in 1% NaCl intake ( Figure S4A ) and decreases in HR ( Figure  S4B ) in all groups. Figure 5 shows the decreases in BP with acute ganglionic blockade in all groups. The reduction in BP response to hexamethonium injection before central treatment and In contrast, the BP reductions induced by hexamethonium in intact females with siRNA-ERα microinjection into these sites were not different from those rats injected with siRNA-SCM ( Figure 5B-5D ).
Effects of Autonomic Blockade on BP
Localization and the Effects of AAV Delivery of siRNA on ERα and ERβ mRNA Expression
The effect of viral delivery of siRNA to knockdown ERα and ERβ in the PVN and RVLM was verified by real-time polymerase chain reaction (RT-PCR) analysis. AAV-siRNA constructs contained a green fluorescent protein (GFP) construct that served as a marker indicating the site of delivery and the cells affected in the PVN and RVLM. Twenty-one days after PVN or RVLM injections of siRNA-ERβ ( Figure 6A-a,b) or siRNA-ERα ( Figure 6A-c,d ), highly robust GFP expression was present in the PVN and RVLM, but not in the subfornical organ (SFO; Figure 6A -e) or the (AP; Figure 6A -f). The PVN injection spreads through the nucleus, and GFP was present in both parvocellular and magnocellular regions. To confirm effective silencing of ERα and ERβ in the PVN and RVLM with these viruses, we performed RT-PCR analyses on the micropunches taken from the PVN and RVLM. As shown in Figure 6B and 6C, ERα and ERβ mRNA levels were reduced by 44% to 74% in rats treated with siRNA-ERα or siRNA-ERβ when compared with rats treated with the control vector, siRNA-SCM. Figure 7A shows representative dihydroethidium (DHE) fluorescent images of cultured PVN neurons with Aldo treatment. Overnight incubation of Aldo induced a 1.9-fold increase in ethidium intensity in siRNA-SCM-treated neurons (n=51; P<0.05) as compared with that seen in PVN neurons with Aldo vehicle incubation (n=25). Treatment with either siRNA-ERα or siRNA-ERβ significantly enhanced this Aldoinduced increase in ROS production (siRNA-ERα, 2.8-fold, n=85; siRNA-ERβ, 3.1-fold, n=90; P<0.05; Figure 7B ).
Effects of Knockdown ERα or ERβ on AldoInduced ROS Production in Cultured PVN Neurons
Discussion
The main findings of this study are (1) both central ERα and ERβ activation played a protective role in the development of Aldo/NaCl-induced hypertension in female rats, (2) PVN or RVLM knockdown of ERβ augmented Aldo/NaCl hypertension in female rats, (3) knockdown of ERα in either the PVN or the RVLM had no significant effect on the Aldo pressor effect, although Aldo induced an increased tendency for BP elevation after bilateral PVN knockdown of ERα, and (4) the brain regions responsible for the protective effects of estrogen interaction with ERα in the development of Aldo/NaCl hypertension in females still need to be determined. These results indicate that the effects of central estrogen are regional and receptor subtype specific for their protective effects against the development of Aldo/NaCl hypertension. It is well established that ERα and ERβ mediate estrogen effects in the cardiovascular system. Each of these receptors is encoded by separate genes, ESR1 and ESR2, respectively. 8 The observation that uterine atrophy occurred in ERα-but not in ERβ-deficient mice provided the first evidence for different functions of ERα and ERβ. 16 Hypertension has been reported only in ERβ but not in ERα knockout mice. 10, 11, 17, 18 Moreover, peripheral application of the ERβ agonist 8β-VE2, but not ERα agonist16α-LE2, decreased elevated BP in spontaneously hypertensive rats. 19 In contrast, activation of either ER subtype attenuates elevated BP level and cardiovascular remodeling in Aldo/salt-treated rats. 20, 21 Previous studies from our laboratory have demonstrated that estrogen activation of ERα, particularly that expressed centrally, is protective against the baroreceptor dysfunction and hypertension induced by angiotensin II in female mice. 10, 11 Together, these results suggest that the functional role of ERα in BP regulation is different depending on the cause or model of hypertension, and that ERβ is a key regulatory factor of BP. The present study confirms and extends these previous studies by showing that central activation of either ERα or ERβ by icv chronic infusions of selective ER agonists attenuates the pressor effects in Aldo/NaCl-treated OVX female rats. In contrast, central blockade of both ER subtypes augments Aldo-induced pressor effects in intact females, suggesting that either central ERα or ERβ may mediate, at least in part, the protective effects of estrogen against Aldo/NaCl-induced hypertension. Moreover, in Aldo/salt-treated rats, the fall in BP in response to ganglionic blockade was less in those with icv infusions of selective ERα or ERβ agonist and was more in those with icv injections of siRNA for ERα or ERβ as compared with their respective controls. These observations add to the previously described studies by establishing the importance of both central ERα and ERβ in the actions against elevated sympathetic activity induced by Aldo.
In rats, studies have shown that ERβ is the predominant ER in the PVN, although ERα mRNA has also been found in this nucleus. 4 Both ERα and ERβ mRNA, as well as protein, are expressed in the RVLM. 4 In studies on immunogold backlabeled PVN neurons with projections to the RVLM, 50% of the cells were found to express ERβ. 22 Thus, the PVN and RVLM may be ideal sites for interaction between ERs and mineralocorticoid receptor (MR) in the regulation of BP and sympathetic nerve activity. In the present study, it was not unexpected to demonstrate that both PVN and RVLM ERβ knockdown augmented Aldo pressor effects, supporting a role for ERβ activation in both the PVN and the RVLM in attenuating the pressor effects of Aldo. Surprisingly, Aldo only induced a slight tendency to increase BP after bilateral PVN knockdown of ERα. Knockdown of ERα in the RVLM had no significant effect. Indeed, recent studies have shown that microinjection of estrogen into the RVLM reduces BP and sympathetic tone. 12 Likewise, estrogen in the PVN attenuates glutamate-induced pressor effects. 7 In both studies, only ERβ agonist mimicked the inhibitory effects of estrogen on these hemodynamic parameters, suggesting estrogen in the RVLM and PVN induces vasodepressor effects mainly via the ERβ-mediated mechanisms. 7, 12 Taken together, we interpret the data as suggestive of a predominant role for ERβ in the PVN and RVLM in mediating the protective effects of estrogen in the development of Aldo hypertension.
The results from the present study also raise the question as to which nucleus/nuclei ERα interacts with MR to play a protective effect in the development of Aldo-induced hypertension. The studies on specific characteristic and subtype-specific expression of ERs in the CNS have shown that ERα is important in the NTS, a nucleus with neurons which receive input from neurons carrying visceral information, and which, in turn, projects directly to the RVLM, PVN, etc. 23 Microinjections of estrogen into the NTS induce increases in parasympathetic tone and baroreceptor sensitivity and a decrease in sympathetic activity in both male and female rats. 5, 6 In angiotensin II-infused rats, the intensity of ERα immunoreactivity increased exclusively in the commissural NTS, whereas neither the number nor the intensity of ERβ-labeled cells changed. 9 Moreover, neurons that contain both MR and the enzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) have been identified in the NTS. 24 Therefore, one could hypothesize that the NTS is a site where ERα interacts with MR to regulate BP. Another possible site where ERα interacts with MR is the lamina terminalis (LT), including the organum vasculosum of the LT, median preoptic nucleus, and SFO. LT structures are involved in both sensing and processing input derived from humoral factors (eg, Aldo and extracellular osmolality) and transmitting this information to the PVN, and thereby could contribute to the regulation of Aldo-induced salt appetite, sympathetic activity, and BP. 25 It has also been shown that LT structures, especially the SFO, have substantial ERα. 4 Therefore, ERα in the NTS or LT structures may be responsible for the protective effects of estrogen in the development of Aldo-induced hypertension. In the present study, in brains with icv injections of siRNAs, we found robust expression of GFP in several nuclei involved in cardiovascular regulation, including the SFO, PVN, RVLM, and NTS. These results may explain the effectiveness of icv, but not PVN/RVLM injections of ERα. In future studies this powerful tool can be used to chronically knockdown ERα in specific nuclei, such as the NTS or LT, to determine which brain areas are responsible for the interaction between estrogen and Aldo.
Zhang et al 26 have reported that icv Aldo resulted in increased DHE staining (indicating oxidative stress) and Fralike activity (indicating neuronal excitation) in neurons of the PVN along with increased sympathetic activity. Previous studies from our laboratory have also shown that icv infusion of apocynin, a NADPH oxidase inhibitor, attenuated systemic Aldo/salt-induced hypertension. 27 Genetic silencing of either NOX2 or NOX4, 2 subunits of NADPH oxidase, with siRNAs in the PVN attenuated Aldo pressor effects. 28 Together these results suggest that Aldo increases sympathetic nerve activity through increased oxidative stress in the hypothalamus. It has been shown that estrogen inhibits angiotensin II-induced hypertension and activation of SFO neurons via interactions with intracellular ROS production. 29 In the present studies, we used confocal microscopy imaging with the fluorescent indicator DHE as an indicator to measure changes in ROS production induced by Aldo in cultured PVN neurons. We found that PVN neurons showed a significant increase in ROS production after overnight incubation with Aldo. The Aldo-induced ROS production was further increased by genetic silencing either ERα or ERβ with siRNAs in the absence of their ligand, estrogen. Recent studies have demonstrated that ERα-or ERβ-dependent activation, molecular regulation, and organ protection may occur in the absence of estrogen. 30, 31 Therefore, the present results suggest that a potential mechanism involved in female protection from Aldo-induced hypertension may involve ER inhibition of MR-induced increases in ROS.
A key feature of the present study that involved the use of AAV delivery of siRNA for selective silencing of ERα or ERβ in the PVN and RVLM was to explore a regional specific effect of these ER subtypes. In agreement with previous studies, 27, 28, 32 icv injections of siRNA induced significant, but incomplete, silencing of ERα or ERβ within brain tissue by 44% to 74%. It should be noted that the incomplete silencing of ER, especially ERα, may still permit partial ER activation to attenuate the pressor effect of Aldo so that the part of augmented pressor effects by knockdown of ERs has been offset. Moreover, mRNA gene expression results do not always reflect the protein expression or activity levels. Nevertheless, ERβ knockdown in either the PVN or the RVLM resulted in significantly potentiating Aldo-induced hypertension, whereas knockdowns of ERα in these nuclei had no significant effect. In addition, the brain areas immediately adjacent to the PVN are the anterior hypothalamus area and ventromedial hypothalamic area. It has been shown that the ventromedial hypothalamic area is a sexually dimorphic group containing many ERα expressing neurons that have extensive projections to areas of the brain involved in autonomic regulation, such as the NTS and RVLM. 4 However, GFP expression in the hypothalamus area and ventromedial hypothalamic area was very low. siRNA injection into the PVN also did not leak into the third ventricle because there was no GFP expression in the SFO or area postrema. Therefore, it is not likely that the effect of blockade of PVN ERα or ERβ on the Aldo-induced pressor response was from antagonism of ERs in the ventromedial hypothalamic area or other nuclei involved in cardiovascular regulation.
Perspectives
Clinical and experimental data indicate important interactions between mineralocorticoid and ER function in cardiovascular diseases. Activation of both ER subtypes in the periphery and the CNS plays a protective role in the development of Aldo/ salt-induced cardiovascular remodeling and hypertension. The present results indicate that both PVN and RVLM ERβ, but not ERα in these nuclei, contribute to the protective effects of estrogen against elevated sympathetic activity and the pressor effects during mineralocorticoid excess. This indicates that there is a regional functional specificity of different ER subtypes in the brain. However, the brain regions responsible for the protective effects of estrogen interaction with ERα in the development of Aldo-induced hypertension still need to be determined.
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None. What Is New?
• These studies demonstrate that both paraventricular nucleus and rostroventrolateral medulla estrogen receptor-β (ERβ), but not ERα in these nuclei, contribute to the protective effects of estrogen against elevated sympathetic activity and the pressor effects during mineralocorticoid excess.
What Is Relevant?
• The demonstration of regional specificity of different ER subtypes in the central nervous system, especially the effect of ERβ in certain nuclei involved in BP regulation, indicates that non-feminizing ERβ agonists have a therapeutic potential in the treatment of some forms of hypertension.
